Related Experiment Video
Updated: Jun 8, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Sorafenib in hepatocellular carcinoma
1ST3 in Medical Oncology, King's College Hospital and Guy's and St Thomas' Hospital, London.
British Journal of Hospital Medicine (London, England : 2005)
|September 21, 2010
Summary
Sorafenib is a standard treatment for advanced liver cancer. This review covers its development, clinical trials, and future applications in hepatocellular carcinoma therapy.
Area of Science:
- Oncology
- Hepatology
- Pharmacology
Background:
- Sorafenib is a multikinase inhibitor approved for advanced hepatocellular carcinoma (HCC).
- It represents a significant advancement in HCC treatment, establishing a new standard of care.
- Understanding the molecular basis of HCC is crucial for targeted therapy development.
Purpose of the Study:
- To review the development of sorafenib for HCC.
- To analyze its journey from molecular carcinogenesis to clinical trials.
- To discuss the future role of sorafenib in HCC management.
Main Methods:
- Literature review of sorafenib's development.
- Analysis of preclinical data on molecular hepatocarcinogenesis.
- Examination of Phase III clinical trial outcomes for sorafenib efficacy and safety.
Main Results:
- Sorafenib's development is rooted in understanding HCC molecular pathways.
- Phase III trials confirmed its efficacy as a standard treatment for advanced HCC.
- The drug's journey highlights the progression of targeted therapies in oncology.
Conclusions:
- Sorafenib has transformed advanced HCC treatment.
- Continued research may further refine its application and explore new therapeutic strategies.
- The development pathway of sorafenib offers insights for future drug discovery in liver cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...